- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06201559
Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions
An Open Label, Balanced, Randomized, Two-Treatment, Four-Period, Two-Sequence, Single Oral Dose, Full Replicate Crossover, Bioequivalence Study of Albendazole Tablets IP 400 mg of Biddle Sawyer Limited (GSK Group Company) With Albendazole Tablets 400 mg of Glaxo SmithKline Consumer Healthcare, South Africa (PTY) Ltd in Healthy, Adult Participants Under Fed Condition
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Gujarat
-
Ahmedabad, Gujarat, India, 382481
- Lambda Therapeutic Research Ltd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy, non-smoker, adult participants having body mass index (BMI) between 18.5 to 30.0 (both inclusive), calculated as weight in kilogram (kg)/ height in meter square (m2)
- Not having any significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12-lead electrocardiogram (ECG) and X-ray chest (postero-anterior view) recordings.
- Able to understand and adhere to the study procedures
- Voluntary written informed consent is given for study participation
- In case of female participants:
Surgically sterilized at least 6 months prior to study participation;Or If of childbearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study, And Serum pregnancy test must be negative.
Exclusion Criteria:
- Known hypersensitivity or idiosyncratic reaction to albendazole or any excipients or any related drug or any substance.
- History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
- Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or non-steroidal anti inflammatory drugs (NSAIDs) induced urticaria.
- History or presence of seizure or psychiatric disorders.
- Ingestion of a medication (prescribed medication & over the counter (OTC) medication, herbal remedies, cimetidine, praziquantel, dexamethasone, ritonavir, phenytoin, carbamazepine, phenobarbital) at any time in 14 days prior to dosing and any vaccine (including COVID-19 vaccine) from 14 days prior to dosing. In any such case participant selection will be at the discretion of the Principal Investigator.
Receipt of an intervention or participation in a drug research study within a period of 90 days prior to the first dose of study intervention **.
- If intervention is received within 90 days where there is no blood loss except safety lab testing, participant can be included considering 10 half-lives duration of intervention received.
- A positive hepatitis screen including hepatitis B surface antigen and/or hepatitis C virus (HCV) antibodies.
- A positive test result for HIV antibody (1 and/or 2).
- The presence of clinically significant abnormal laboratory values during screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence TRTR
Participants will be administered with test (T) intervention [Albendazole Indian Pharmacopoeia (IP) 400 mg] in Period 1, reference (R) intervention (Albendazole Tablets 400 mg) in Period 2, T intervention in Period 3 and R intervention in Period 4.
|
Albendazole IP 400 mg tablets will be administered under fed conditions
|
Experimental: Sequence RTRT
Participants will be administered with reference (R) intervention in Period 1, test (T) intervention in Period 2, R intervention in Period 3 and T intervention in Period 4.
|
Albendazole 400 mg tablets will be administered under fed conditions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum plasma concentration (Cmax) of Albendazole
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Area under the plasma concentration curve from time 0 to the last measured [AUC(0-t)] for Albendazole
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum plasma concentration (Cmax) of Albendazole sulfoxide
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Area under the plasma concentration curve from time 0 to the last measured [AUC(0-t)] of Albendazole sulfoxide
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Area under the plasma concentration-time curve extrapolated to infinity [AUC0-∞] of Albendazole and Albendazole sulfoxide
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Time until Cmax is reached (Tmax) for Albendazole and Albendazole sulfoxide
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Plasma concentration half-life (t1/2) of Albendazole and Albendazole sulfoxide
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Lambda-z (λz) [Terminal elimination rate constant] of Albendazole and Albendazole sulfoxide
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
AUC_% Extrap_obs (observed percentage of extrapolated area under concentration) for Albendazole and Albendazole sulfoxide
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Number of participants with adverse events (AE)
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Absolute values of vital signs: Blood pressure [millimeters of mercury (mmHg)
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Absolute values of vital signs: Respiratory rate [breaths per minute (bpm)
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Absolute values of vital signs: Radial pulse [beats per minute (bpm)
Time Frame: Up to 24 hours post dose
|
Up to 24 hours post dose
|
Change from baseline in vital signs: Blood pressure [millimeters of mercury (mmHg)
Time Frame: Baseline (Day 1) and up to 24 hours post dose
|
Baseline (Day 1) and up to 24 hours post dose
|
Change from baseline in vital signs: Respiratory rate [breaths per minute (bpm)
Time Frame: Baseline (Day 1) and up to 24 hours post dose
|
Baseline (Day 1) and up to 24 hours post dose
|
Change from baseline in vital signs: Radial pulse [beats per minute (bpm)
Time Frame: Baseline (Day 1) and up to 24 hours post dose
|
Baseline (Day 1) and up to 24 hours post dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Diseases
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antiprotozoal Agents
- Antiparasitic Agents
- Anthelmintics
- Antiplatyhelmintic Agents
- Anticestodal Agents
- Albendazole
Other Study ID Numbers
- 221030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intestinal Diseases
-
Maastricht University Medical CenterCatharina Ziekenhuis EindhovenCompleted
-
University of NottinghamNorthern Care Alliance NHS Foundation Trust; Cambridge University Hospitals... and other collaboratorsRecruiting
-
Jinling Hospital, ChinaCompletedChronic Intestinal Pseudo ObstructionChina
-
MovetisCompletedChronic Intestinal Pseudo-ObstructionUnited Kingdom
-
Sohag UniversityRecruitingIntestinal Parasites in Patients With Intestinal CancerEgypt
-
Alfasigma S.p.A.Active, not recruitingChronic Intestinal Pseudo-obstructionBelgium, Italy, Spain
-
SterileCare Inc.Not yet recruitingPediatric Intestinal Failure
-
Mayo ClinicFujifilm Medical Systems USA, Inc.CompletedGastro-Intestinal DisorderUnited States
-
St. Jude Children's Research HospitalNot yet recruiting
-
Tallaght University HospitalRoyal College of Surgeons, IrelandRecruitingGastro-Intestinal DisorderIreland
Clinical Trials on Albendazole IP 400 mg
-
Swiss Tropical & Public Health InstitutePublic Health Laboratory Ivo de CarneriCompletedTrichuris Trichiura; InfectionTanzania
-
Jennifer KeiserPublic Health Laboratory Ivo de CarneriCompletedHookworm Infections | Helminthes; Infestation, Intestinal | Ascariasis | TrichuriasisTanzania
-
Noguchi Memorial Institute for Medical ResearchGhana Health ServicesCompleted
-
Dr. Reddy's Laboratories LimitedXenoPort, Inc.Completed
-
Makerere UniversityMinistry of Health, Uganda; World BankCompleted
-
Jennifer KeiserPublic Health Laboratory Ivo de CarneriNot yet recruitingHookworm Infections | Ascariasis | TrichuriasisTanzania
-
Dr. Reddy's Laboratories LimitedCompleted
-
Jennifer KeiserCentre Suisse de Recherches Scientifiques en Cote d'IvoireCompletedHookworm Infections | Ascariasis | TrichuriasisCôte D'Ivoire
-
Jennifer KeiserPublic Health Laboratory Ivo de CarneriNot yet recruitingHookworm Infections | Ascariasis | TrichuriasisTanzania
-
Daiichi Sankyo, Inc.CompletedHealthy VolunteersUnited States